Mizuho Raises BrightSpring (BTSG) PT to $45 Despite Signs of Peak Healthcare Demand

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best young stocks to buy and hold for 3 years. On January 9, Mizuho analyst Ann Hynes raised the firm’s price target on BrightSpring Health to $45 from $42, while keeping an Outperform rating on the shares. As part of its Q4 2o25 preview, Mizuho revised targets for healthcare facilities and managed care after a physician survey revealed a sequential slowdown in utilization growth. The firm noted that because this deceleration occurred despite favorable year-over-year comparisons, it likely signals that the current peak in healthcare demand is behind us.

On January 7, Wells Fargo increased its price target for BrightSpring Health Services Inc. (NASDAQ:BTSG) to $43 from $39, while maintaining an Overweight rating. In a broader assessment of the healthcare sector, the firm expressed the highest confidence in Medicare Advantage among managed care organizations, while noting significant uncertainty regarding Medicaid and Exchange markets.

Wells Fargo anticipated a more difficult environment for hospitals in 2026 as post-pandemic growth trends fade and legislative risks increase. For medical distributors, the firm noted an ongoing debate in the market over whether earnings revisions or valuation multiples will drive stock performance.

BrightSpring Health Services Inc. (NASDAQ:BTSG) operates as a home and community-based healthcare services platform in the US. It operates through two segments: Pharmacy Solutions and Provider Services.

While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.